Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?

Rheumatology (Oxford). 2020 Mar 1;59(3):464-466. doi: 10.1093/rheumatology/kez522.

Michael Hughes^{1

2}, Dinesh Khanna³, John D Pauling^{4

5}

¹ Department of Rheumatology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
² Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
³ University of Michigan Scleroderma Program, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
⁴ Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, UK.
⁵ Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.

No abstract available

Publication types